Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Venous thromboembolism (VTE) is a burden on healthcare systems. Standard treatment involves parenteral anticoagulation overlapping with a vitamin K antagonist, an approach that is effective but associated with limitations including the need for frequent coagulation monitoring. The direct oral anticoagulant rivaroxaban is similarly effective to standard therapy as a single-drug treatment for VTE and does not require routine coagulation monitoring. The objective of this economic evaluation was to estimate the cost-effectiveness of rivaroxaban compared with standard VTE treatment from a UK perspective. METHODS: A Markov model was constructed using data and probabilities derived from the EINSTEIN DVT and EINSTEIN PE studies of rivaroxaban and other published sources. Health outcomes included VTE rates, bleeding events avoided, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). RESULTS: There was greater discounted quality-adjusted life expectancy with rivaroxaban than with standard therapy, irrespective of indication and treatment duration. Rivaroxaban was associated with per-patient cost savings for each treatment duration modelled (3, 6 and 12 months), and these were greatest with shorter durations. Rivaroxaban was found to be dominant (cheaper and more effective) and, therefore, cost-effective, in both patients with deep vein thrombosis and pulmonary embolism in all three treatment duration groups, and was also cost-effective in patients requiring lifelong anticoagulation (ICERs: £8677 per QALY and £7072 per QALY in patients with index deep vein thrombosis and pulmonary embolism, respectively). The cost-effectiveness of rivaroxaban was largely insensitive to variations in one-way sensitivity analysis. Probabilistic sensitivity analysis demonstrated that at a threshold of £20,000 per QALY, rivaroxaban had a consistent probability of being cost-effective, compared with LMWH/VKA treatment, of around 80% regardless of index VTE or duration of anticoagulation therapy (3, 6, 12 months or lifelong). CONCLUSIONS: This analysis suggests that rivaroxaban represents a cost-effective choice for acute treatment of deep vein thrombosis and pulmonary embolism and secondary prevention of VTE in the UK, compared with LMWH/VKA treatment, regardless of the required treatment duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“All of them suggested that DOACs are costeffective relative to VKA. 100,104-116”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119 · cited 1×
“Current standard of care consists of initial treatment with a parenteral anticoagulant, often low molecular weight heparin (LMWH; administered by subcutaneous injection) overlapping with a vitamin K antagonist (VKA), typically warfarin [11-13].”
BackgroundScottish Intercollegiate Guidelines Network
Twaddle, S., & Qureshi, S. (2005) · Evidence-based Healthcare and Public Health · doi:10.1016/j.ehbc.2005.09.008 · Cited by 4,084
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
Pengo, V., Lensing, A. W. A., Prins, M. H., Marchiori, A., Davidson, B. L., Tiozzo, F., Albanese, P., Biasiolo, A., Pegoraro, C., Iliceto, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032274 · Cited by 1,828
Research works printed but not linked: 2
- Cohen A, Martinez C, Wallenhorst C, Bamber L. Vitamin K antagonist treatment patterns and persistence after venous thromboembolism in non-cancer patients: VTE Epidemiology Group (VEG) Study [abstract]. J Thromb Haemost. 2013;11:27–8. Abstract AS 17.2.
- Eerenberg ES, Middeldorp S, Levi M, Lensing AWA, Buller HR. What is the clinical impact of major bleedings with rivaroxaban? Results from the pooled EINSTEIN studies [abstract]. J Thromb Haemost. 2013;11:88. Abstract OC02.2.
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“All of them suggested that DOACs are costeffective relative to VKA.(100,104-116)”
BackgroundManagement of Pulmonary Embolism
Konstantinides, S. V., Barco, S., Lankeit, M., & Meyer, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.061 · Cited by 330
European Union-28: An annualised cost-of-illness model for venous thromboembolism
Barco, S., Woersching, A. L., Spyropoulos, A. C., Piovella, F., & Mahan, C. E. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-08-0670 · Cited by 179
Barco, S., Lankeit, M., Binder, H., Schellong, S., Christ, M., Beyer‐Westendorf, J., Duerschmied, D., Bauersachs, R. M., Empen, K., Held, M., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0004 · Cited by 48
Robinson, R., Wirt, T. C., Barbosa, C., Amidi, A., Chen, S., Joseph, R. M., & Fleischer, A. E. (2018) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2017.12.001 · Cited by 23
Metadata
- Authors
- Bamber, L., Muston, D., McLeod, E., Guillermin, A., Lowin, J., & Patel, R.
- Affiliations
- Bayer (Germany) (DE)
- Bayer (United States) (US)
- IQVIA (United States) (US)
- King's College Hospital (GB)
- Corresponding author
- Bamber, Luke
- Venue
- Thrombosis Journal
- Published
- 2015-06-11
- Volume
- 13
- Issue
- 1
- Pages
- 20-20
- ISSN
- 1477-9560 (ISSN-L)
- PMC
- PMC4464718
- OpenAlex
- W2144328416
- Cited by
- 42
- References
- 53
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 6 · 2018: 6 · 2017: 5 · 2016: 5 · 2015: 2
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Thrombosis Journal (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Bayer HealthCare
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- venous thromboembolism, rivaroxaban, low molecular weight heparin, vitamin K antagonists, cost-effectiveness, deep vein thrombosis, pulmonary embolism, direct oral anticoagulants, quality-adjusted life years, bleeding risk, anticoagulation duration, secondary prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. https://app.cochat.ai/papers/10.1186/s12959-015-0051-3
- The paper
- Bamber, L., Muston, D., McLeod, E., Guillermin, A., Lowin, J., & Patel, R. (2015). Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thrombosis Journal. https://doi.org/10.1186/s12959-015-0051-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.